<SEC-DOCUMENT>0000950170-25-002487.txt : 20250106
<SEC-HEADER>0000950170-25-002487.hdr.sgml : 20250106
<ACCEPTANCE-DATETIME>20250106201600
ACCESSION NUMBER: 0000950170-25-002487
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20250103
FILED AS OF DATE: 20250106
DATE AS OF CHANGE: 20250106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lian Brian
CENTRAL INDEX KEY: 0001614578
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37355
FILM NUMBER: 25513179
MAIL ADDRESS:
STREET 1: C/O SEELOS THERAPEUTICS, INC.
STREET 2: 300 PARK AVENUE, 12TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viking Therapeutics, Inc.
CENTRAL INDEX KEY: 0001607678
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 461073877
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-704-4660
MAIL ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>
<schemaVersion>X0508</schemaVersion>
<documentType>4</documentType>
<periodOfReport>2025-01-03</periodOfReport>
<issuer>
<issuerCik>0001607678</issuerCik>
<issuerName>Viking Therapeutics, Inc.</issuerName>
<issuerTradingSymbol>VKTX</issuerTradingSymbol>
</issuer>
<reportingOwner>
<reportingOwnerId>
<rptOwnerCik>0001614578</rptOwnerCik>
<rptOwnerName>Lian Brian</rptOwnerName>
</reportingOwnerId>
<reportingOwnerAddress>
<rptOwnerStreet1>C/O VIKING THERAPEUTICS, INC.</rptOwnerStreet1>
<rptOwnerStreet2>9920 PACIFIC HEIGHTS BLVD, SUITE 350</rptOwnerStreet2>
<rptOwnerCity>SAN DIEGO</rptOwnerCity>
<rptOwnerState>CA</rptOwnerState>
<rptOwnerZipCode>92121</rptOwnerZipCode>
<rptOwnerStateDescription></rptOwnerStateDescription>
</reportingOwnerAddress>
<reportingOwnerRelationship>
<isDirector>true</isDirector>
<isOfficer>true</isOfficer>
<isTenPercentOwner>false</isTenPercentOwner>
<isOther>false</isOther>
<officerTitle>President & CEO</officerTitle>
</reportingOwnerRelationship>
</reportingOwner>
<aff10b5One>false</aff10b5One>
<nonDerivativeTable>
<nonDerivativeTransaction>
<securityTitle>
<value>Common Stock, par value $0.00001 per share</value>
</securityTitle>
<transactionDate>
<value>2025-01-03</value>
</transactionDate>
<transactionCoding>
<transactionFormType>4</transactionFormType>
<transactionCode>A</transactionCode>
<equitySwapInvolved>false</equitySwapInvolved>
</transactionCoding>
<transactionAmounts>
<transactionShares>
<value>92800</value>
<footnoteId id="F1"/>
</transactionShares>
<transactionPricePerShare>
<value>0</value>
</transactionPricePerShare>
<transactionAcquiredDisposedCode>
<value>A</value>
</transactionAcquiredDisposedCode>
</transactionAmounts>
<postTransactionAmounts>
<sharesOwnedFollowingTransaction>
<value>2397727</value>
</sharesOwnedFollowingTransaction>
</postTransactionAmounts>
<ownershipNature>
<directOrIndirectOwnership>
<value>D</value>
</directOrIndirectOwnership>
</ownershipNature>
</nonDerivativeTransaction>
<nonDerivativeTransaction>
<securityTitle>
<value>Common Stock, par value $0.00001 per share</value>
</securityTitle>
<transactionDate>
<value>2025-01-03</value>
</transactionDate>
<transactionCoding>
<transactionFormType>4</transactionFormType>
<transactionCode>A</transactionCode>
<equitySwapInvolved>false</equitySwapInvolved>
</transactionCoding>
<transactionAmounts>
<transactionShares>
<value>163333</value>
<footnoteId id="F2"/>
</transactionShares>
<transactionPricePerShare>
<value>0</value>
</transactionPricePerShare>
<transactionAcquiredDisposedCode>
<value>A</value>
</transactionAcquiredDisposedCode>
</transactionAmounts>
<postTransactionAmounts>
<sharesOwnedFollowingTransaction>
<value>2561060</value>
</sharesOwnedFollowingTransaction>
</postTransactionAmounts>
<ownershipNature>
<directOrIndirectOwnership>
<value>D</value>
</directOrIndirectOwnership>
</ownershipNature>
</nonDerivativeTransaction>
<nonDerivativeTransaction>
<securityTitle>
<value>Common Stock, par value $0.00001 per share</value>
</securityTitle>
<transactionDate>
<value>2025-01-06</value>
</transactionDate>
<transactionCoding>
<transactionFormType>4</transactionFormType>
<transactionCode>S</transactionCode>
<equitySwapInvolved>false</equitySwapInvolved>
</transactionCoding>
<transactionAmounts>
<transactionShares>
<value>175490</value>
<footnoteId id="F3"/>
</transactionShares>
<transactionPricePerShare>
<value>42.6838</value>
<footnoteId id="F4"/>
</transactionPricePerShare>
<transactionAcquiredDisposedCode>
<value>D</value>
</transactionAcquiredDisposedCode>
</transactionAmounts>
<postTransactionAmounts>
<sharesOwnedFollowingTransaction>
<value>2385570</value>
</sharesOwnedFollowingTransaction>
</postTransactionAmounts>
<ownershipNature>
<directOrIndirectOwnership>
<value>D</value>
</directOrIndirectOwnership>
</ownershipNature>
</nonDerivativeTransaction>
<nonDerivativeTransaction>
<securityTitle>
<value>Common Stock, par value $0.00001 per share</value>
</securityTitle>
<transactionDate>
<value>2025-01-06</value>
</transactionDate>
<transactionCoding>
<transactionFormType>4</transactionFormType>
<transactionCode>S</transactionCode>
<equitySwapInvolved>false</equitySwapInvolved>
</transactionCoding>
<transactionAmounts>
<transactionShares>
<value>19000</value>
<footnoteId id="F3"/>
</transactionShares>
<transactionPricePerShare>
<value>43.3169</value>
<footnoteId id="F5"/>
</transactionPricePerShare>
<transactionAcquiredDisposedCode>
<value>D</value>
</transactionAcquiredDisposedCode>
</transactionAmounts>
<postTransactionAmounts>
<sharesOwnedFollowingTransaction>
<value>2366570</value>
</sharesOwnedFollowingTransaction>
</postTransactionAmounts>
<ownershipNature>
<directOrIndirectOwnership>
<value>D</value>
</directOrIndirectOwnership>
</ownershipNature>
</nonDerivativeTransaction>
</nonDerivativeTable>
<derivativeTable>
<derivativeTransaction>
<securityTitle>
<value>Stock Option (Right to Buy)</value>
</securityTitle>
<conversionOrExercisePrice>
<value>42.89</value>
</conversionOrExercisePrice>
<transactionDate>
<value>2025-01-03</value>
</transactionDate>
<transactionCoding>
<transactionFormType>4</transactionFormType>
<transactionCode>A</transactionCode>
<equitySwapInvolved>false</equitySwapInvolved>
</transactionCoding>
<transactionAmounts>
<transactionShares>
<value>78300</value>
</transactionShares>
<transactionPricePerShare>
<value>0</value>
</transactionPricePerShare>
<transactionAcquiredDisposedCode>
<value>A</value>
</transactionAcquiredDisposedCode>
</transactionAmounts>
<exerciseDate>
<value>2026-01-03</value>
<footnoteId id="F6"/>
</exerciseDate>
<expirationDate>
<value>2035-01-03</value>
</expirationDate>
<underlyingSecurity>
<underlyingSecurityTitle>
<value>Common Stock</value>
</underlyingSecurityTitle>
<underlyingSecurityShares>
<value>78300</value>
</underlyingSecurityShares>
</underlyingSecurity>
<postTransactionAmounts>
<sharesOwnedFollowingTransaction>
<value>78300</value>
</sharesOwnedFollowingTransaction>
</postTransactionAmounts>
<ownershipNature>
<directOrIndirectOwnership>
<value>D</value>
</directOrIndirectOwnership>
</ownershipNature>
</derivativeTransaction>
</derivativeTable>
<footnotes>
<footnote id="F1">Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award.</footnote>
<footnote id="F2">The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2024, 33.33% of which vested on January 3, 2025 upon the achievement of a non-financial performance goal.</footnote>
<footnote id="F3">These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards and certain performance restricted stock unit awards.</footnote>
<footnote id="F4">The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.19 to $43.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.</footnote>
<footnote id="F5">The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.19 to $43.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.</footnote>
<footnote id="F6">25% of the shares subject to the option will vest on each anniversary of the grant date.</footnote>
</footnotes>
<ownerSignature>
<signatureName>/s/ Michael Morneau, as Attorney-in-Fact</signatureName>
<signatureDate>2025-01-06</signatureDate>
</ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>